Taken together, these observations revealed that RNF182 expression is inhibited in NSCLC tumor tissues and that its low expression in NSCLC patients is associated with poor clinical outcome, indicating that NSCLC progression is associated with RNF182 alteration. Here, RNF182 is linked to neoplasm.